Stock Ratings / Health Care / CGC / forecast

USNA (61) SNDL (61) ACB (58) OBIO (28) ⌘ Pro Terminal →

Canopy Growth Corporation (CGC) 12-Month Stock Forecast & Price Target Cone

Q: What is CGC's 12-month stock price target?

Canopy Growth Corporation (CGC) carries a 12-month consensus base price target of $0.66 (-2.9% from $0.68), with a bull-case target of $2.5 and a bear-case floor of $0.51.

Q: Is CGC stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates CGC D (Sell — SELL) with an RQD Confidence score of 51/100.

$0.68 +0.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Canopy Growth Corporation (CGC) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $285.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-2.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CGC)Realized 20D OHLCV Swing Band: ±12.3%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CGC Position Size: $10,000

Shares at $0.68: 14705.9 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.51

$7,500

$-2,500 (-25.0%)

12M Consensus BaseTarget $0.66

$9,706

$-294 (-2.9%)

12M Bull Case BreakoutTarget $2.50

$36,765

+$26,765 (+267.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$2	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CGC)

✓Walkthrough of CGC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CGC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.74%▼ DESCENDING CHANNEL

2026-10-30O $0.69H $0.69L $0.64C $0.68VOL 2.28M

RES: $1.03SUP: $0.61SMA50: $0.87SMA200: $1.00

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CGC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CGC Butterfly Map → + Track CGC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CGC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CGC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CGC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CGC)

Health Care Rank #335 of 1016 ⚔️ USNA vs CGC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CGC vs. USNA, SNDL, ACB, OBIO)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Canopy Growth Corporation (CGC) ranks #335 by composite RQD confidence (51/100, grade D) and #526 by equity capitalization ($285.6M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. USNA currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with CGC at 51/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CGC ACTIVE Canopy Growth Corporation	D	51/100	—	—	—	+0.46%	$285.6M	Benchmark Subject
USNA USANA Health Sciences Inc.	C-	61/100	24.6x	78.3%	7.9%	-1.91%	$265.0M	/usna-vs-cgc →
SNDL SNDL Inc.	C-	61/100	—	—	—	+0.78%	$316.3M	/sndl-vs-cgc →
ACB Aurora Cannabis Inc.	D+	58/100	—	—	—	0.00%	$252.8M	/acb-vs-cgc →
OBIO Orchestra BioMed Holdings Inc.	E	28/100	—	96.0%	-35.0%	+1.67%	$366.0M	/obio-vs-cgc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001737927

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Canopy Growth Corporation (CGC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$189.0M, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, CGC closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$0	-$189.0M	—	—	—	—
FY2024 (FY)	2025-03-31	$0	-$354.0M	—	—	—	—
FY2023 (FY)	2024-03-31	$0	-$526.0M	—	—	—	—

3. CGC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CGC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Canopy Growth Corporation (NASDAQ: CGC) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $0.68 (+0.46% 1D, market cap $285.6M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, CGC ranks #335 in composite RQD confidence.

How does CGC compare to USNA and SNDL in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), CGC carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, USNA (USANA Health Sciences Inc.) holds a C- grade (61/100 RQD, P/E 24.6x, ROIC 7.9%, cap $265.0M) and SNDL (SNDL Inc.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $316.3M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CGC?

Per CGC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001737927), Canopy Growth Corporation generated $0 in revenue, -$189.0M in net income, and $0 in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CGC trading relative to its 50-day, 200-day, and 52-week technical levels?

CGC last traded at $0.68 (+0.46% on volume of 1,131,833 shares), positioning the stock -21.84% below its 50-day simple moving average ($0.87) and -32.00% below its 200-day simple moving average ($1.00). Across its 52-week range of $0.64 to $2.38, CGC sits at the 2.3% percentile with a 14-day RSI of 24.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.3% ($1.00 to $0.76).

CGC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CGC's 12-month stock price target?

Canopy Growth Corporation (CGC) carries a 12-month consensus base price target of $0.66 (-2.9% from $0.68), with a bull-case target of $2.5 and a bear-case floor of $0.51.